Medically reviewed by Lindsay Cook, PharmDMedically reviewed by Lindsay Cook, PharmD Inhalers for chronic obstructive ...

The FDA has approved an expanded label for GlaxoSmithKline’s new Trelegy Ellipta inhaler ... Breo Ellipta and Anoro Ellipta. Trelegy is also indicated to reduce exacerbations of COPD in patients ...

Do not initiate in rapidly or acutely deteriorating COPD or asthma. Not for use with other long-acting β 2-agonists. Do not exceed recommended dose. Prescribe a short-acting, inhaled β 2-agonist ...

Companies like AstraZeneca and GSK, which have high-revenue-generating inhalers for asthma and chronic obstructive pulmonary disorder (COPD ... followed by Relvar/Breo Ellipta and Seretide ...

Companies like AstraZeneca and GSK, which have high-revenue-generating inhalers for asthma and chronic obstructive pulmonary ...